In vitro activity of ofloxacin against Mycobacterium tuberculosis

Ming Chih Yu, Jen Suo, Tao Ping Lin, Kwen Tay Luh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

For the past 3 years, ofloxacin has been widely used in treating patients with drug-resistant tuberculosis in Taiwan. To study its usefulness in treating these patients, 139 isolates of Mycobacterium tuberculosis from patients treated at the Taiwan Provincial Chronic Disease Control Bureau from September 1994 to September 1995 were tested to determine the in vitro antituberculosis activity of ofloxacin. Of these, 131 had not been previously exposed to ofloxacin, and 130 (99.2%) were susceptible to ofloxacin. Sixty-four isolates were found to be susceptible to all conventional antituberculosis drugs, and all of these were also susceptible to ofloxacin. Of the remaining 67 isolates that were resistant to one or more conventional antituberculosis drugs, 66 (98.5%) were susceptible to ofloxacin. There was no association between susceptibility of ofloxacin and susceptibility to conventional antituberculosis drugs among the isolates tested. Of the eight isolates of M. tuberculosis previously exposed to ofloxacin, seven (87.5%) were resistant. Our results indicate that patients with multidrug-resistant strains of M. tuberculosis who have not received prior ofloxacin treatment may be safely treated with ofloxacin, even without knowing the result of pretreatment ofloxacin susceptibility tests. We also found that ofloxacin resistance emerges frequently. Therefore, an adequate combination of antituberculosis drugs, along with ofloxacin, should be prescribed to prevent the development of resistance to ofloxacin.

Original languageEnglish
Pages (from-to)13-16
Number of pages4
JournalJournal of the Formosan Medical Association = Taiwan yi zhi
Volume96
Issue number1
Publication statusPublished - Jan 1997
Externally publishedYes

Fingerprint

Ofloxacin
Mycobacterium tuberculosis
In Vitro Techniques
Taiwan
Pharmaceutical Preparations
Multidrug-Resistant Tuberculosis
Drug Combinations

Keywords

  • multidrug resistance
  • Mycobacterium tuberculosis
  • ofloxacin
  • Taiwan

ASJC Scopus subject areas

  • Medicine(all)

Cite this

In vitro activity of ofloxacin against Mycobacterium tuberculosis. / Yu, Ming Chih; Suo, Jen; Lin, Tao Ping; Luh, Kwen Tay.

In: Journal of the Formosan Medical Association = Taiwan yi zhi, Vol. 96, No. 1, 01.1997, p. 13-16.

Research output: Contribution to journalArticle

@article{2d8dd4117d38477682b9c524b1483f02,
title = "In vitro activity of ofloxacin against Mycobacterium tuberculosis",
abstract = "For the past 3 years, ofloxacin has been widely used in treating patients with drug-resistant tuberculosis in Taiwan. To study its usefulness in treating these patients, 139 isolates of Mycobacterium tuberculosis from patients treated at the Taiwan Provincial Chronic Disease Control Bureau from September 1994 to September 1995 were tested to determine the in vitro antituberculosis activity of ofloxacin. Of these, 131 had not been previously exposed to ofloxacin, and 130 (99.2{\%}) were susceptible to ofloxacin. Sixty-four isolates were found to be susceptible to all conventional antituberculosis drugs, and all of these were also susceptible to ofloxacin. Of the remaining 67 isolates that were resistant to one or more conventional antituberculosis drugs, 66 (98.5{\%}) were susceptible to ofloxacin. There was no association between susceptibility of ofloxacin and susceptibility to conventional antituberculosis drugs among the isolates tested. Of the eight isolates of M. tuberculosis previously exposed to ofloxacin, seven (87.5{\%}) were resistant. Our results indicate that patients with multidrug-resistant strains of M. tuberculosis who have not received prior ofloxacin treatment may be safely treated with ofloxacin, even without knowing the result of pretreatment ofloxacin susceptibility tests. We also found that ofloxacin resistance emerges frequently. Therefore, an adequate combination of antituberculosis drugs, along with ofloxacin, should be prescribed to prevent the development of resistance to ofloxacin.",
keywords = "multidrug resistance, Mycobacterium tuberculosis, ofloxacin, Taiwan",
author = "Yu, {Ming Chih} and Jen Suo and Lin, {Tao Ping} and Luh, {Kwen Tay}",
year = "1997",
month = "1",
language = "English",
volume = "96",
pages = "13--16",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - In vitro activity of ofloxacin against Mycobacterium tuberculosis

AU - Yu, Ming Chih

AU - Suo, Jen

AU - Lin, Tao Ping

AU - Luh, Kwen Tay

PY - 1997/1

Y1 - 1997/1

N2 - For the past 3 years, ofloxacin has been widely used in treating patients with drug-resistant tuberculosis in Taiwan. To study its usefulness in treating these patients, 139 isolates of Mycobacterium tuberculosis from patients treated at the Taiwan Provincial Chronic Disease Control Bureau from September 1994 to September 1995 were tested to determine the in vitro antituberculosis activity of ofloxacin. Of these, 131 had not been previously exposed to ofloxacin, and 130 (99.2%) were susceptible to ofloxacin. Sixty-four isolates were found to be susceptible to all conventional antituberculosis drugs, and all of these were also susceptible to ofloxacin. Of the remaining 67 isolates that were resistant to one or more conventional antituberculosis drugs, 66 (98.5%) were susceptible to ofloxacin. There was no association between susceptibility of ofloxacin and susceptibility to conventional antituberculosis drugs among the isolates tested. Of the eight isolates of M. tuberculosis previously exposed to ofloxacin, seven (87.5%) were resistant. Our results indicate that patients with multidrug-resistant strains of M. tuberculosis who have not received prior ofloxacin treatment may be safely treated with ofloxacin, even without knowing the result of pretreatment ofloxacin susceptibility tests. We also found that ofloxacin resistance emerges frequently. Therefore, an adequate combination of antituberculosis drugs, along with ofloxacin, should be prescribed to prevent the development of resistance to ofloxacin.

AB - For the past 3 years, ofloxacin has been widely used in treating patients with drug-resistant tuberculosis in Taiwan. To study its usefulness in treating these patients, 139 isolates of Mycobacterium tuberculosis from patients treated at the Taiwan Provincial Chronic Disease Control Bureau from September 1994 to September 1995 were tested to determine the in vitro antituberculosis activity of ofloxacin. Of these, 131 had not been previously exposed to ofloxacin, and 130 (99.2%) were susceptible to ofloxacin. Sixty-four isolates were found to be susceptible to all conventional antituberculosis drugs, and all of these were also susceptible to ofloxacin. Of the remaining 67 isolates that were resistant to one or more conventional antituberculosis drugs, 66 (98.5%) were susceptible to ofloxacin. There was no association between susceptibility of ofloxacin and susceptibility to conventional antituberculosis drugs among the isolates tested. Of the eight isolates of M. tuberculosis previously exposed to ofloxacin, seven (87.5%) were resistant. Our results indicate that patients with multidrug-resistant strains of M. tuberculosis who have not received prior ofloxacin treatment may be safely treated with ofloxacin, even without knowing the result of pretreatment ofloxacin susceptibility tests. We also found that ofloxacin resistance emerges frequently. Therefore, an adequate combination of antituberculosis drugs, along with ofloxacin, should be prescribed to prevent the development of resistance to ofloxacin.

KW - multidrug resistance

KW - Mycobacterium tuberculosis

KW - ofloxacin

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=0031058451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031058451&partnerID=8YFLogxK

M3 - Article

VL - 96

SP - 13

EP - 16

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 1

ER -